Results of the 3-year SURMOUNT-1 study reflect the longest trial to date of tirzepatide in adults with overweight/obesity and risk for developing T2D.

Younger US veterans with PTSD and type 2 diabetes who no longer met criteria for PTSD were less likely to initiate insulin and had reduced odds of mortality.

Anila Chadha, MD, highlights key preventive strategies to reduce CVD risk in patients with obesity and how to tailor them to address individual patient needs.

Investigators found as much as a 2-fold difference in being diagnosed with dementia across the US, even after controlling for common individual risk factors.

Researchers observed substantial disparities in burden by cancer type, age group, countries/territories, and a country's level of Human Development Index.

Your daily dose of the clinical news you may have missed.

The influenza/COVID-19 combination did not prove noninferior to the comparator flu vaccine against influenza B, the companies reported.

Primary care clinicians can screen at-risk individuals for type 1 diabetes with a single autoantibody panel. It pays to test and educate early, according to this author.

If approved the selective NaV1.8 pain signal inhibitor would reflect the first new class of pain management medication in more than 20 years.

Your daily dose of the clinical news you may have missed.

The approval of neffy (epinephrine nasal spray) could help individuals and caregivers act sooner and feel safer treating a type 1 allergic reaction.

White coat and masked hypertension can be elusive and dangerous. Click through a topline look at recommendations from the 2017 ACC/AHA hypertension guidelines.

Steven Furr, MD, discusses how communication between clinicians and patients is crucial to combatting vaccine hesitancy this upcoming respiratory virus season.

Conversely, greater intake of animal-based fat was associated with an increased risk of overall and CVD mortality, authors reported.

Of the 25 routine lab tests studied, none proved clinically useful for diagnosing COVID-19, even among participants with a high long COVID symptom burden.

No health system across the 28 analyzed in this study demonstrated appropriate SGLT2i prescribing for more than 25% of eligible individuals.

The AHEAD study program will use plasma biomarker screening, novel PET agents, and other unique approaches to assessing lecanemab effect at the earliest stage of disease.

Following a decrease, suicide rates among US preteens increased annually by 8.2% from 2008 to 2022, according to a recent cross-sectional study.

Your daily dose of the clinical news you may have missed.

Incretin analogues, an oral glucose formulation that targets endogenous nutrient-sensing pathways and a cannabinoid receptor 1 antagonist are in the new mix.